Table 2.
Transition probabilities of health states on different drug therapies for 6 months for patients with RA in Zanzibar.
| Intervention | Health state | Transition probability1 | Range High Low |
Source | |
|---|---|---|---|---|---|
| Methotrexate | Remission LDA MDA HDA |
0.09 0.34 0.38 0.19 |
0.0675 0.255 0.285 0.1425 |
0.1125 0.425 0.475 0.2375 |
(32, 33) |
| Triple therapy | Remission LDA MDA HDA |
0.10 0.41 0.33 0.16 |
0.75 0.3075 0.2475 0.12 |
1.25 0.5125 0.4125 0.20 |
(34) |
| b/tsDMARD 1 (early)2 | Remission LDA MDA HDA |
0.12 0.46 0.28 0.14 |
0.15 0.345 0.21 0.105 |
0.18 0.575 0.35 0.175 |
(35) |
| b/tsDMARD 1 (late)3 | Remission LDA MDA HDA |
0.11 0.41 0.32 0.16 |
0.0825 0.3075 0.24 0.12 |
0.1375 0.5125 0.4 0.20 |
(36) |
| b/tsDMARD2 (early)2 | Remission LDA MDA HDA |
0.12 0.30 0.39 0.19 |
0.09 0.225 0.2925 0.1425 |
0.15 0.375 0.4875 1.125 |
(37) |
| b/tsDMARD 2 (late)3 | Remission LDA MDA HDA |
0.12 0.25 0.42 0.21 |
0.09 0.1875 0.315 0.1575 |
0.15 0.3125 0.525 0.2625 |
(37) |
1
Transition probability from one health state to another. All patients start at moderate disease activity.
2
Early—drug is started after methotrexate failure.
3
Late—treatment after both methotrexate and triple therapy failure.